{"entity":{"id":"tinzaparin","kind":"drug","name":"Tinzaparin","aka":["tinzaparin sodium"],"tldr":"Tinzaparin is a once-daily blood-thinning injection used in the UK and Europe to treat and prevent clots, including long-term treatment of a clot in people with active cancer.","summary":"The UK SmPC for the 20,000 IU/mL vials covers treatment of deep vein thrombosis and pulmonary embolism and \"extended treatment of venous thromboembolism and prevention of recurrences in adult patients with active cancer\"; the 10,000 IU/mL vials cover prophylaxis in surgery, \"particularly orthopaedic, general or oncological surgery\", and in immobilised medical patients including those with active cancer. In the US, Innohep was labelled for acute DVT with or without pulmonary embolism given with warfarin (DailyMed SPL). Among the evidence for LMWH, ITAC 2022 cites the randomised trial of tinzaparin against warfarin in active cancer (Lee et al., JAMA 2015).","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Tinzaparin_sodium","links":[{"label":"UK SmPC (emc): tinzaparin 20,000 IU/ml (treatment, extended treatment in active cancer)","url":"https://www.medicines.org.uk/emc/product/13848/smpc"},{"label":"UK SmPC (emc): tinzaparin 10,000 IU/ml (prophylaxis)","url":"https://www.medicines.org.uk/emc/product/13847/smpc"},{"label":"US label (DailyMed): Innohep (historic US label)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1513b960-d9d1-11de-8a1e-0002a5d5c51b"},{"label":"Farge et al., 2022 international clinical practice guidelines (ITAC) for the treatment and prophylaxis of venous thromboembolism in patients with cancer (Lancet Oncol 2022)","url":"https://doi.org/10.1016/S1470-2045(22)00160-7"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":["enoxaparin","dalteparin","warfarin"],"cancers":[],"sections":[],"technologies":["cancer-associated-thrombosis"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["vte"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Innohep","modality":"Low-molecular-weight heparin (injection)","supportive":true,"mechanism":"A low-molecular-weight heparin of porcine origin that potentiates antithrombin's inhibition of activated clotting factors, mainly factor Xa (UK SmPC 5.1).","approvals":[{"region":"UK","year":1994,"indication":"Treatment of DVT and PE; extended treatment of venous thromboembolism and prevention of recurrences in adults with active cancer","note":"Year is the first authorisation of UK licence PL 00043/0192 (20,000 IU/ml vials) as printed in its SmPC; the cancer indication came later"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tinzaparin/","neighbours":{"drug":[{"id":"dalteparin","kind":"drug","name":"Dalteparin","route":"/drugs/dalteparin/"},{"id":"enoxaparin","kind":"drug","name":"Enoxaparin","route":"/drugs/enoxaparin/"},{"id":"warfarin","kind":"drug","name":"Warfarin","route":"/drugs/warfarin/"}],"technology":[{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/"}],"term":[{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/"}]}}